80 related articles for article (PubMed ID: 30656969)
1. Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer.
Loi M; Dunant A; Ghith S; Cascales-Garcia AM; Mazouni C; Pistilli B; Mathieu MC; Deutsch E; Arriagada R; Rivera S
Cancer Invest; 2019; 37(1):29-38. PubMed ID: 30656969
[TBL] [Abstract][Full Text] [Related]
2. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer.
Akay CL; Ueno NT; Chisholm GB; Hortobagyi GN; Woodward WA; Alvarez RH; Bedrosian I; Kuerer HM; Hunt KK; Huo L; Babiera GV
Cancer; 2014 May; 120(9):1319-28. PubMed ID: 24510381
[TBL] [Abstract][Full Text] [Related]
3. Once-daily radiation therapy for inflammatory breast cancer.
Brown L; Harmsen W; Blanchard M; Goetz M; Jakub J; Mutter R; Petersen I; Rooney J; Stauder M; Yan E; Laack N
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):997-1003. PubMed ID: 24721591
[TBL] [Abstract][Full Text] [Related]
4. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
6. Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer.
Bates T; Williams NJ; Bendall S; Bassett EE; Coltart RS
Breast; 2012 Jun; 21(3):330-5. PubMed ID: 22410111
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.
Adkins D; Brown R; Trinkaus K; Maziarz R; Luedke S; Freytes C; Needles B; Wienski D; Fracasso P; Pluard T; Moriconi W; Ryan T; Hoelzer K; Safdar S; Rearden T; Rodriguez G; Khoury H; Vij R; DiPersio J
J Clin Oncol; 1999 Jul; 17(7):2006-14. PubMed ID: 10561251
[TBL] [Abstract][Full Text] [Related]
9. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
10. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
[TBL] [Abstract][Full Text] [Related]
11. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
[TBL] [Abstract][Full Text] [Related]
13. The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer.
Yan Y; Tang L; Tong W; Zhou J
Sci Rep; 2016 May; 6():25874. PubMed ID: 27174789
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
[TBL] [Abstract][Full Text] [Related]
15. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E; Bertucci F; Pierga JY; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; van Laere S; Ueno NT; Toiron Y; Finetti P; Birnbaum D; Borg JP; Viens P; Chinot O; Gonçalves A
Oncotarget; 2016 Apr; 7(14):18531-40. PubMed ID: 26921265
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.
Wu SG; Zhang WW; Wang J; Dong Y; Sun JY; Chen YX; He ZY
Future Oncol; 2019 Feb; 15(5):507-516. PubMed ID: 30378451
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of inflammatory and non-inflammatory locally advanced breast cancer - the experience of a Moroccan hospital].
Benbrahim Z; Berrada A; Amaadour L; Zahra El M'rabet F; Elfatemi H; Elfakir S; Mellas N; Arifi S
Gynecol Obstet Fertil Senol; 2017 Nov; 45(11):604-608. PubMed ID: 29100820
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
Ueno NT; Buzdar AU; Singletary SE; Ames FC; McNeese MD; Holmes FA; Theriault RL; Strom EA; Wasaff BJ; Asmar L; Frye D; Hortobagyi GN
Cancer Chemother Pharmacol; 1997; 40(4):321-9. PubMed ID: 9225950
[TBL] [Abstract][Full Text] [Related]
19. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer.
Loap P; Nicaise B; Laki F; Loirat D; Pierga JY; Fourquet A; Kirova Y
Strahlenther Onkol; 2023 Jan; 199(1):30-37. PubMed ID: 35648170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
